Abstract
High-dose cyclophosphamide (high-CY) is a potent immunosuppressive regimen that is increasingly used to mitigate both autoimmune and alloimmune conditions. Differential expression of aldehyde dehydrogenase between hematopoietic stem cells and lymphocytes accounts for the differential sensitivity of these cells to high-CY and explains why this regimen is immunosuppressive but not myeloablative. This article describes the clinical translation of high-CY for the treatment of autoimmune and alloimmune conditions.
Publication types
-
Research Support, N.I.H., Extramural
-
Review
MeSH terms
-
Autoimmune Diseases / drug therapy*
-
Autoimmune Diseases / immunology
-
Bone Marrow Transplantation
-
Clinical Trials as Topic
-
Cyclophosphamide / administration & dosage*
-
Cyclophosphamide / therapeutic use
-
Graft vs Host Disease / immunology
-
Graft vs Host Disease / prevention & control*
-
Hematopoietic Stem Cells / drug effects
-
Hematopoietic Stem Cells / immunology
-
Humans
-
Immunosuppressive Agents / administration & dosage*
-
Immunosuppressive Agents / therapeutic use
-
Lymphocytes / drug effects
-
Lymphocytes / immunology
-
Transplantation, Homologous / adverse effects
Substances
-
Immunosuppressive Agents
-
Cyclophosphamide